Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

106.98 -0.43 (-0.40%)
Official Closing Price Updated: 7:00 PM EST, Feb 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Merck Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Patients With Persistent, Recurrent or Metastatic Cervical Cancer
From Merck & Co., Inc.
Via Business Wire
Merck Announces the Kenneth C. Frazier Award for Maternal Health Equity to Accelerate Progress Towards Improved Birth Outcomes for All
SOURCE: Merck & Co., Inc. 
Via 3BL Media
Merck to Participate in the Guggenheim Biopharma Strategy Series
From Merck & Co., Inc.
Via Business Wire
Merck Announces the Kenneth C. Frazier Award for Maternal Health Equity to Accelerate Progress towards Improved Birth Outcomes for All
From Merck & Co., Inc.
Via Business Wire
Merck Announces Supply Agreement with U.S. Government for Molnupiravir, an Investigational Oral Antiviral Candidate for Treatment of Mild to Moderate COVID-19
From Merck & Co., Inc.
Via Business Wire
New Data on KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus Sunitinib in First-Line Treatment for Patients With Advanced Renal Cell Carcinoma From Pivotal Phase 3 CLEAR/KEYNOTE-581 Trial Presented at 2021 ASCO Annual Meeting
From Merck & Co., Inc.
Via Business Wire
LYNPARZA® (olaparib) Reduced the Risk of Invasive Disease Recurrence or Death by 42% Versus Placebo in Adjuvant Treatment of Patients With Germline BRCA Mutations and High-Risk HER2-Negative Early Breast Cancer in Phase 3 OlympiA Trial
From Merck & Co., Inc.
Via Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Given After Surgery Reduced the Risk of Disease Recurrence or Death by 32% Versus Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC)
From Merck & Co., Inc.
Via Business Wire
Merck Announces Completion of Organon & Co. Spinoff
From Merck & Co., Inc.
Via Business Wire
Merck and Sanofi’s First and Only Six-in-One Pediatric Combination Vaccine Now Available in the United States
From Merck & Co., Inc.
Via Business Wire
Merck Announces Third-Quarter 2021 Dividend
From Merck & Co., Inc.
Via Business Wire
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as First-Line Treatment for Certain Patients With Esophageal Cancer or HER2-Negative Gastroesophageal Junction (GEJ) Adenocarcinoma
From Merck & Co., Inc.
Via Business Wire
The Companies Tackling A Global Health Crisis
Via FinancialNewsMedia
Merck Announces Positive Topline Results from PNEU-DIRECTION (V114-027) and PNEU-PLAN (V114-024) Phase 3 Pediatric Studies for V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine
From Merck & Co., Inc.
Via Business Wire
Merck Named to 100 Best Corporate Citizens of 2021
SOURCE: Merck & Co., Inc. 
Via 3BL Media
Topics Climate Change
Exposures Climate
Psychedelics Move to The Forefront of Innovative Research as the FDA Approves Large-Scale Testing
Via FinancialNewsMedia
Exposures Product Safety
Merck Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-Free Survival (EFS) in Patients With High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
From Merck & Co., Inc.
Via Business Wire
Merck Declares Record Date and Dividend for the Organon & Co. Spinoff
From Merck & Co., Inc.
Via Business Wire
Merck Highlights Scientific Data at 2021 ASCO Annual Meeting Across More Than 20 Cancer Types From Broad Oncology Research Program
From Merck
Via Business Wire
Merck and Eisai Receive Priority Review From FDA for KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Applications for Advanced Renal Cell Carcinoma and for Advanced Endometrial Carcinoma
From Merck & Co., Inc.
Via Business Wire
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
From Merck & Co., Inc.
Via Business Wire
Merck Hosts Organon Investor Day Outlining New Company’s Vision, Focus and Business Model for Sustained Growth
From Merck & Co., Inc.
Via Business Wire
Merck Announces First-Quarter 2021 Financial Results
From Merck & Co., Inc.
Via Business Wire
Merck to Hold Investor Briefing Featuring Organon on May 3
From Merck & Co., Inc.
Via Business Wire
Amid Humanitarian Crisis in India, Merck Announces Voluntary Licensing Agreements with Five Indian Generics Manufacturers to Accelerate and Expand Global Access to Molnupiravir, an Investigational Oral Therapeutic for the Treatment of COVID-19
From Merck & Co., Inc.
Via Business Wire
Merck Accelerates Climate Goals; Announces Carbon Neutrality in Operations by 2025
From Merck & Co., Inc.
Via Business Wire
Merck Accelerates Climate Goals; Announces Carbon Neutrality in Operations by 2025
SOURCE: Merck & Co., Inc. 
Via 3BL Media
Topics Climate Change Emissions Intellectual Property
Exposures COVID-19 Climate Intellectual Property
Merck to Discontinue Development of MK-7110 for COVID-19
From Merck & Co., Inc.
Via Business Wire
Merck and Ridgeback Biotherapeutics Provide Update on Progress of Clinical Development Program for Molnupiravir, an Investigational Oral Therapeutic for the Treatment of Mild-to-Moderate COVID-19
From Merck & Co., Inc.
Via Business Wire
Merck Expands Safer Childbirth Cities Initiative to 20th Community-Led Project Advancing Maternal Health Equity During Black Maternal Health Week
SOURCE: Merck & Co., Inc. 
Via 3BL Media
Topics Death
Exposures Death
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.